Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy.
Sign Up to like & getrecommendations! Published in 2021 at "American journal of hematology"
DOI: 10.1002/ajh.26395
Abstract: The progress with intensive chemotherapy and supportive care measures has improved survival in patients with newly diagnosed acute myeloid leukemia (AML). Given the recent development of effective low intensity therapies, an optimal decision on the… read more here.
Keywords: acute myeloid; intensive chemotherapy; week mortality; mortality ... See more keywords
Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Hematology"
DOI: 10.1007/s12185-022-03334-8
Abstract: Acute myeloid leukemia (AML) predominantly affects elderly adults, and its prognosis worsens with age. Treatment options for patients in Japan ineligible for intensive chemotherapy include cytarabine/aclarubicin ± granulocyte colony-stimulating factor (CA ± G), azacitidine (AZA), low-dose cytarabine (LDAC), targeted… read more here.
Keywords: intensive chemotherapy; japan ineligible; treatment; outcomes patients ... See more keywords
Proton beam therapy for adolescent primary central nervous system lymphoma with residual tumor after intensive chemotherapy: a case report.
Sign Up to like & getrecommendations! Published in 2019 at "Practical radiation oncology"
DOI: 10.1016/j.prro.2019.05.005
Abstract: Primary central nervous system lymphoma (PCNSL) is a very rare type of non-Hodgkin lymphoma. Although pediatric and adolescent PCNSL patients generally respond well to intensive chemotherapy, the salvage treatment for this condition remains uncertain for… read more here.
Keywords: chemotherapy; residual tumor; intensive chemotherapy; pcnsl ... See more keywords
Hypomethylating agents combined with low-dose chemotherapy for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: a real-world clinical experience.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of chemotherapy"
DOI: 10.1080/1120009x.2022.2097433
Abstract: This study aimed to assess the efficacy and safety of hypomethylating agent (HMA)-based regimens in the treatment of older adult patients with acute myeloid leukaemia (AML), unfit for standard induction chemotherapy. Treatment outcomes and prognostic… read more here.
Keywords: intensive chemotherapy; unfit intensive; dose chemotherapy; patients acute ... See more keywords
ETMR-10. EARLY FOCAL RADIOTHERAPY AND TEMOZOLOMIDE FOLLOWING COMPLETE RESECTION APPEAR SUPERIOR TO INTENSIVE CHEMOTHERAPY AND DELAYED RADIOTHERAPY IN CHILDREN WITH EMBRYONAL TUMORS WITH MULTILAYERED ROSETTES (ETMR)
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa222.214
Abstract: Abstract BACKGROUND Embryonal tumor with multilayered rosettes (ETMR) is a rare, aggressive embryonal central nervous system tumor characterized by LIN28A expression and alterations in the C19MC locus. ETMRs predominantly occur in young children, have a… read more here.
Keywords: chemotherapy; radiotherapy; focal radiotherapy; early focal ... See more keywords
RARE-12. EARLY FOCAL RADIOTHERAPY AND TEMOZOLOMIDE FOLLOWING COMPLETE RESECTION APPEAR SUPERIOR TO INTENSIVE CHEMOTHERAPY IN CHILDREN WITH EMBRYONAL TUMORS WITH MULTILAYERED ROSETTES (ETMR)
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz175.935
Abstract: Embryonal tumor with multilayered rosettes (ETMR) is an extremely rare entity characterized by LIN28A expression and alterations in the C19MC locus. ETMRs predominantly occur in young children and have a dismal prognosis. We report on… read more here.
Keywords: chemotherapy; focal radiotherapy; intensive chemotherapy; resection ... See more keywords
Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutic Advances in Hematology"
DOI: 10.1177/2040620719882822
Abstract: Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a globally poor outcome, especially in patients ineligible for intensive chemotherapy. Until recently, therapeutic options for these patients included low-dose cytarabine (LDAC) or the hypomethylating… read more here.
Keywords: venetoclax; ineligible intensive; patients ineligible; intensive chemotherapy ... See more keywords
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Hematology"
DOI: 10.1177/20406207221081637
Abstract: Background: Evidence that a venetoclax (VEN)-combined regimen is effective in relapsed/refractory acute myeloid leukemia (R/R AML) is emerging. However, it is unknown how VEN-combined low intensity treatment compares to intensive chemotherapy (IC) in medically fit… read more here.
Keywords: salvage; intensive chemotherapy; ven combination; relapsed refractory ... See more keywords
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2018-10-879866
Abstract: The prevention of relapse is the major therapeutic challenge in older patients with acute myeloid leukemia (AML) who have obtained a complete remission (CR) on intensive chemotherapy. In this randomized phase 3 study (HOVON97) in… read more here.
Keywords: maintenance; intensive chemotherapy; group; azacitidine maintenance ... See more keywords
Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-125662
Abstract: Introduction: On November 2018 the FDA approved the treatment of venetoclax together with hypomethylating agent (HMA) or low dose cytarabine (LDAC) for newly diagnosed AML patients who cannot tolerate intensive chemotherapy. There is limited data… read more here.
Keywords: relapsed refractory; venetoclax; venetoclax given; intensive chemotherapy ... See more keywords
Intensive chemotherapy (IC) versus hypomethylating agents (HMA) for the treatment of younger patients with myelodysplastic syndrome (MDS) and elevated bone marrow blasts.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7064
Abstract: 7064Background: The AZA-001 trial has shown a survival advantage for patients with high-risk MDS treated with HMA as compared to IC. However, this study was conducted mainly in an older population.... read more here.
Keywords: versus hypomethylating; chemotherapy versus; intensive chemotherapy; hypomethylating agents ... See more keywords